Thread by @BigBiteNow

1/8
Firstly a hearty congratulations to #SKIN on their progress to date and their announcement today.

Some #AVCT thoughts.

SKIN RNS 13th July ;
"Once initial testing on the Affimers is completed over the next few weeks,"

2/8
"validation of the sensors on the real SARS-CoV-2 virus will be carried out at the containment level 3 ("CL3") laboratory in the University of Aberdeen."

"Upon successful completion of the evaluation, Integumen and the Avacta will enter into a supply agreement"

3/8
Furthermore ;
"Microtox BT has undergone extensive internal testing"

"Microtox PD has now successfully completed initial spike protein testing and validation"

and detects "the spike protein of SARS-CoV-2 in real-time for those with a high viral load."

4/8
SKIN RNS 24th Sept ;
"Further to the announcement of 13 July 2020. . . the evaluation of under the MTA has been successful and consequently a Memorandum of Understanding has been signed with Avacta for a commercial agreement, subject to contract."

5/8
So (internal) studies and validation to date, just like with AVCTs other Covid related programmes, have demonstrated enough to make a commercial agreement worthwhile.

So again we have further demonstration that Affimers can be effective, in yet another form of diagnostics.

6/8
There is still much to learn about this particular deal but what I really like about all this, is that Affimers led diagnostics, keep proving themselves to be commercially effective.

The AVCT Covid story remains a big one but I really am more excited by, is what the

7/8
combination of this progress (studies, relationships, experience, partnerships, department growth, ISO accreditation, revenues), will now go on to deliver for the AVCT platform in the future.

AVCTs own moonshot, are of course the Cancer therapies but time and again, I keep

8/8
saying it, that the diagnostic pipeline, driven by Covid, can and I think will, really deliver for AVCT and their shareholders.

All of which offers a fantastic opportunity to truly explore said therapy opportunities, whilst giving shareholders a really solid invest platform.

8A
#AVCT RNS 6th Aug ;

"expanding product development team. . . experienced in-vitro diagnostic Product Development Manager."

"expanding our protein production facilities in order to meet the expected demand. . . for the Covid-19 tests"

8B
But also for "future diagnostic tests in the pipeline."

All of which is being driven and paid for by the £48m raised back in June this year. So its not a case of when we receive this, we will. . .

Its happening now. So I look forward to Monday's update.